Insmed

Insmed Goodwill/Assets

The Goodwill to Total Assets Ratio of Insmed (INSM) as of Nov 18, 2026 is 6.01 %. In the previous year, Goodwill to Total Assets Ratio was 6.72 % — a change of -10.57% (lower).

Goodwill/Assets

6.01 %

YoY

-10.57%

Last updated:

Goodwill to Total Assets Ratio of Insmed is 2025 6.01 % . Goodwill to Total Assets Ratio of Insmed was 2024 6.72 % . It decreases by -10.57% lower compared to the previous year.

The Insmed Goodwill/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill/Assets
Date
Goodwill/Assets
Jan 1, 2018
9.71 USD
Jan 1, 2019
7.23 USD
Jan 1, 2020
6.19 USD
Jan 1, 2021
10.95 USD
Jan 1, 2022
8.22 USD
Jan 1, 2023
10.24 USD
Jan 1, 2024
6.72 USD
Jan 1, 2025
6.01 USD
The Insmed Goodwill/Assets history
YEARGoodwill/AssetsYoY
6.01 %-10.57%
6.72 %-34.34%
10.24 %+24.56%
8.22 %-24.93%
10.95 %+76.90%
6.19 %-14.44%
7.23 %-25.49%
9.71 %-22.95%
12.60 %-48.50%
24.46 %+49.84%
16.32 %-35.25%
25.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Insmed Stock analysis

What does Insmed do? Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insmed stock

Goodwill to Total Assets Ratio of Insmed is 6.01 % in 2025.

Goodwill to Total Assets Ratio of Insmed changed from 6.72 % to 6.01 %, representing a -10.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio Insmed since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's Insmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Insmed

All Key Metrics — Insmed